Objective To study the pathogenesis, diagnosis and treatment of Crohn disease of urinary bladder. Methods 4 cases of Crohn diseases of urinary bladder treated were reviewed. Results 2 cases manifestated clinically as acute appendicitis,resultig in enterovesical fistulas formation in 1.Granulomatous pseudotumors were observed on cystoscopy in 3.The diagnosis was missed preoperatively in all the 4,being finally acertained on pathological studies. Conclusions In case of an ileovesical fistulas of unknown cause or the finding of papollomatous mucosal hyperplasia and bullous edema on cystoscopy,Crohn disease of the bladder should be thought of.Resection of the involved bladder wall will be necessary.

Objective To assess the efficacy and safety of transurethral resection of the prostate(PKRP) and bladder tumor(PKRBT) with plasmakinetic energy. Methods 300 patients(mean age of 71.6 years;range from 52 to 91) with symptomatic BPH without suspected cancer (confirmed by IPSS,urinary flow rate,ultrasonographic estimate and PSA tests) were treated by PKRP. 37 patients with superficial transitional cell carcinoma (17 with tumors appearing at the lateral wall) were treated by PKRBT.All patients were followed up for 1～6 months postoperatively. Results For PKRP,the duration of the procedure was (48?31) min(range 13 to 98 min).No case need blood transfusion during the operation.No transurethral resection syndrom occurred.The mean catheterization time was 2 days (1 to 4 days). The peak flow rate increased from (5.2?3.9) to (19.2?4.1),(21.8?4.6),(22.3?5.7)ml/s at 1,3 and 6 months respectively. The IPSS decreased from 24.7 to 5.7, 5.4,5.0 and the QOL decreased from 5.3 to 1.7,1.8,1.2 at 1,3 and 6 months respectively.For PKRBT,the duration of the procedure was (24?13) min(range 5 to 39 min) with little bleeding.The adductor reflex was found in 5 of the 17 cases with tumor located at the lateral wall. Conclusions It is suggested that transurethral bipolar plasmakinetic resection of the prostate and bladder tumor is effective and safe. This pilot series permits a comparative study with conventional TUR system.

OBJECTIVETo evaluate the erectile function of the patient with premature ejaculation.

METHODSQuestionnaires of Chinese Indes of Erectile Function (CIEF-5) were issued to 522 patients with premature ejaculation.

RESULTSOf the subjects invertigated, 341 (65.33%) claimed to have the problem of ED with premature ejaculation, and 433 (82.95%) scored below standard in CIEF-5. There was significant difference between the two groups.

CONCLUSIONSPremature ejaculation could significantly influence patients' self-esteem about their erectile function and hence their proper scores in CIEF-5. In most of the patients of premature ejaculation with different degres of erectile dysfunction, only a few with significantly low scores in CIEF-5 had premature ejaculation complicated with ED.

Adult ; Aged ; Aged, 80 and over ; Ejaculation ; Erectile Dysfunction ; diagnosis ; physiopathology ; Humans ; Male ; Middle Aged ; Penile Erection

Objective:To systematically evaluate effects of different treatment schemes before allogeneic-hematopoietic stem cell transplantation (allo-HSCT) on the long-term relapse and survival of patients with myelodysplastic syndrome (MDS) after transplantation.Methods:The related literatures were searched from databases of Ovid, Cochrane Library, PubMed, Embase, CNKI, VIP, WanFang and CBM from inception to December 2019. And then 2 reviewers independently extracted data, assessed methodological quality and crosschecked on the included literatures. According to the treatment methods, the cases included in the literatures were divided into demethylation drug (decitabine or azacytidine) treatment (demethylation treatment group) and traditional treatment regimen (including chemotherapy and support treatment) (traditional treatment group). RevMan 5.3 software was used to analyze overall survival (OS), recurrence, non-relapse mortality (NRM) and relapse free survival (RFS).Results:Finally, 10 articles were included. The results of meta-analysis showed that in the traditional treatment group, the differences of 3-year OS rate [44.6% (146/327) vs. 35.5%(138/389); OR = 0.93, 95% CI 0.38-2.27, P = 0.87], the recurrence rate [32.4% (106/327) vs. 37.3% (145/389); OR = 1.00, 95% CI 0.49-2.05, P = 0.99], NRM [26.3% (86/327) vs. 27.0% (105/389); OR = 1.05, 95% CI 0.75-1.49, P = 0.77], RFS rate [9.2% (30/327) vs. 12.6% (49/389); OR = 0.74, 95% CI 0.26-2.10, P = 0.57] between the chemotherapy group and the support treatment group were not statistically significant. The differences of 3-year OS rate [40.7% (165/405) vs. 45.9% (290/632); OR = 0.98, 95% CI 0.71-1.36, P = 0.28], recurrence rate [32.6% (132/405) vs. 38.3% (242/632); OR = 1.05, 95% CI 0.79-2.05, P = 0.25], NRM [27.2% (110/405) vs. 24.8% (157/632); OR = 0.81, 95% CI 0.59-1.11, P = 0.68], RFS rate [46.7% (189/405) vs. 42.2 (267/632); OR = 0.84, 95% CI 0.63-1.12, P = 0.85] between demethylation treatment group and traditional treatment group were not statistically significant. There were no significant differences in 3-year OS rate, recurrence rate, NRM and RFS rate between demethylation treatment group and chemotherapy group, demethylation treatment group and support treatment group (all P > 0.05). Conclusion:Different treatment regimens before allo-HSCT have no significant effect on survival or recurrence after transplantation for patients with MDS.